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Abstract
This paper examines the knowledge bases of the world’s largest pharmaceuticals groups by
sales. It puts forward the concepts of knowledge  breadth and  depth as the relevant
dimensions along which knowledge bases can be mapped. Breadth is studied by analysing
the evolution of specialisation by scientific field over time. It hints at the widening range of
bodies of scientific and technological knowledge relevant to firms’ innovative activities.
Depth (or integration) is studied by analysing the evolution of specialisation across
different typologies of research. It hints at the complex, non-linear interdependencies that
link the scientific and technological domains. We develop the analyses on the strength of an
original database of 33,127 EPO patents, and of 41,931 ‘non patent document’ citations (of
which 19,494 were identified as scientific articles included in the ISI databases). The
groups studied seem to have incrementally increased the breadth of their knowledge bases,
moving toward the fields proper of the new bio-pharmaceutical research trajectory. At the
same time, some of the groups studied exhibit remarkable depth in knowledge
specialisation in particular fields such as biotechnology, biochemical research and
neurosciences. Finally, this paper also provides a first methodological test of possible
problems deriving from the use of ‘unidentified’ patent citations (i.e. added by the
examiners together with those proposed by the inventor). We compare a random sample of
these citations with a sample of citations explicitly added by the original inventor, and
compare the results in terms of scientific specialisations.
Key words: Knowledge Breadth, Depth, Integration, Patent Citations, Scientific
Publications, Pharmaceuticals.
JEL: O3, L2, L653
1. Introduction
This paper builds upon previous research into the knowledge boundaries of firms. In recent
years, empirical and theoretical research has bestowed considerable attention on issues
related to the changing characteristics of firms’ knowledge bases. In particular, some
authors argue that there is considerable support for the hypothesis that the knowledge bases
relevant to firms’ innovative activities are increasing in breadth, i.e. in their range of useful
disciplines, and depth, i.e. in their analytical complexity (e.g. Granstrand, Patel and Pavitt,
1997; Wang and von Tunzelmann, 2001). This trend is often associated with the emergence
of new ways of organising and coordinating innovative processes that rely not only on the
activities of a few, large and integrated innovating firms, but more on networks of
innovators that share the burden of developing new products and processes (e.g. Powell,
1990; Arora and Gambardella, 1994). This paper aims at developing indicators that capture
some key characteristics of the knowledge bases of the firms that coordinate these networks
of innovating organisations in the case of the world pharmaceutical industry.
Indeed, alongside the increasing importance of networks of innovators, recent research
based on in-depth case studies of industries and firms highlights the pivotal role played by
firms that maintain wide capabilities to be able to act as network coordinators. These firms
have been termed ‘systems integrators’ (Prencipe, 1997; Miller et al., 1995). Systems
integrator firms rely on wide science and technology (S&T) capabilities to co-ordinate,
from an organisational and technological viewpoint, the manufacturing and research
activities they have outsourced. On this basis, it has been argued that the ‘knowledge
boundaries’ of (systems integrator) firms differ from their ‘production boundaries’ and that
the ‘knowledge’ and ‘product’ domains evolve according to different principles (Brusoni
and Prencipe, 2001). The integration and co-ordination of dispersed, decentralised
knowledge-acquisition processes may require further knowledge-related investment that
allows (some) firms to act as ‘loci of integration.’ This observation is particularly important
for economic analysis because it governs the extent to which knowledge-related inputs, at
the level of the firm, can be expected to be accurate indicators of the knowledge available
to the firm. When a firm is able to draw on more extensive networks of knowledge and is
able to effectively coordinate these dispersed sources of knowledge generation, traditional
approaches to understanding the relationship between inputs and outputs are challenged.
This paper develops indicators and methodologies to tackle quantitatively the issue of what
are the specific characteristics of the knowledge bases of those firms that rely on, and
coordinate, networks of specialised suppliers of both equipment and knowledge. To answer
this, the paper examines the knowledge bases of the world’s largest pharmaceuticals groups
by sales. In recent years the pharmaceutical industry has attracted considerable attention
from scholars of industrial economics and technical change, and recent research has
highlighted the key coordinating role played by large pharmaceutical firms with respect to
their (increasingly) wide networks of suppliers of very specialised knowledge (Orsenigo,
Pammolli and Riccaboni, 2001).
We develop the analysis on the strength of an original database of 33,127 EPO patents, and
of 41,931 ‘non patent document’ citations (of which 19,494 were identified as scientific
articles included in the ISI databases). We analyse two key indicators. First, we assess4
firms’ specialisation patterns (and their evolution during the 1990s) at the scientific level
relying on the analysis of citations from patents to scientific literature. The analysis of
specialisation by scientific discipline captures changes in the breadth of firms’ knowledge
bases. Second, we analyse firms’ specialisation patterns in terms of the different types of
research and development activities they perform. This analysis is made possible by the
Computer Horizons Inc. (CHI) classification, which links scientific journals to specific
types of research and development (e.g. clinical observation, a mix of clinical observation
and clinical investigation, and clinical investigation and basic research). The analysis of
specialisation by type of research (within each discipline) is an indication of the depth of
firms’ knowledge bases.
The paper is structured as follows. Section 2 describes the key dimensions of firms’
knowledge bases that will be analysed and why the pharmaceutical industry was chosen for
this study. Section 3 discusses the methodology of citation analysis and presents the data
sources on which this paper builds. Section 4 develops the quantitative analysis of the
breadth and depth of groups’ knowledge bases and Section 5 discusses the robustness of the
results. Finally, Section 6 concludes.
1.  The changing structure of knowledge accumulation
The issue of integration and co-ordination of labour is of great relevance as it directly
impinges upon the evolution of the key input to innovative activities: knowledge. As early
as 1945, von Hayek considered that the key economic problem was ‘the problem of the
utilization of knowledge not given to anyone in its entirety’. In what follows, we maintain
that the principle of specialisation applies to the process of developing new bodies of
knowledge. Knowledge develops through the generation of branches and sub-branches of
increasing depth and specificity (Loasby, 1999). The principle of specialisation applies at
the level of: (a) disciplines, e.g. physics, chemical engineering, economics; (b) institutions,
e.g. firms’ R&D laboratories, government research centres, universities; and (c) functions,
e.g. corporate R&D units, engineering units, business development units (Patel and Pavitt,
1998: 4). These areas intersect in complex ways. Knowledge generated through division
and specialisation is both incomplete and dispersed. Such incompleteness and dispersion
appear to be inherent properties of knowledge itself.
Incompleteness implies that learning processes cannot converge to any state of rest, as such
a state does not exist: knowledge cannot be defined as a closed and well defined set of
events that only some form of bounded rationality prevents from being fully discovered.
Dispersion relates to one of the main functions performed by organisations: the co-
ordination and integration of heterogeneous learning processes. Given the inherent
limitations of human cognition, idiosyncratic learning processes need to be ‘completed’ by
being embedded in a suitable institutional framework (Loasby, 1999). The (increasing)
variety of the knowledge bases relevant to firms’ innovative activities underlines the
importance of the analysis of the mechanisms and processes that allow coordination of
specialised learning processes to be achieved.
2.1. The dimensions of knowledge specialisation: breadth and depth
 Within industry studies type research, Granstrand, Patel, and Pavitt (1997) found that large5
firms are more diversified in terms of the technologies that they master than in the products
that they make, and that their technological diversity has been increasing while typically
their product range has narrowed. Similar results have emerged from studies of highly
innovative sectors, such as aero-engines (Prencipe, 1997), telecommunications
infrastructure (Davies, 1997), and hard disk drives (Chesborough and Kusunoki, 2000).
Other evidence is emerging from detailed studies of traditional sectors such as chemical
engineering (Brusoni, 2001), tyres (Acha and Brusoni, 2002), oil exploration (Acha, 2002)
and automotives (Takeishi, 2002).
Moreover, these studies confirm that (some) firms within networks of vertically related
companies maintain S&T capabilities over a set of fields wider than can be justified by only
their in house activities. In other words, some firms appear to be specialised in terms of the
number of activities they carry out in house, while at the same time maintaining wide (and
even widening) in-house scientific and technological capabilities. These firms have been
labelled in existing research ‘systems integrators’ (Prencipe, 1997). These firms ‘know
more than they make’ which allows them to act as problem solvers of last resort should, for
example, contingencies emerge anywhere in the value chain (Brusoni, Prencipe and Pavitt,
2001).
Past research on systems integration activities have highlighted the dimensions along which
the characteristics of the knowledge bases on which integrating firms rely should be
evaluated (Prencipe, 2000). First, integrating firms need to maintain capabilities on most (if
not all) the bodies of scientific and technological knowledge that impinge upon the
development of the specific product market in which they compete. We call this dimension
breadth. Breadth is studied by analysing the evolution of specialisation by scientific field
over time. It hints at the widening range of bodies of scientific and technological
knowledge relevant to firms’ innovative activities. Breadth of knowledge base is necessary
for firms interested in maintaining a leading innovative role, playing the role of ‘intelligent
customer’ for their suppliers, and being able to recognise at an early stage new and
promising technological developments, and identifying and abandoning as quickly as
possible unsuitable development paths.
Breadth is not the only dimension that matters, though. Firms’ investments in specific
bodies of knowledge vary according to their perceived importance within firms’ strategies.
For example, Granstrand, Patel, and Pavitt (1997) argued that firms’ capabilities could be
classified as distinctive, background, niche or marginal. In other words, whether a specific
body of knowledge is used to define the operating principle of any given artefact (e.g.
combustion in automotive), or whether it is perceived as a possible development that might
revolutionise that artefact in the distant future (e.g. cell fuel technology in automotive), or
whether it is part of the firm strategy to remain an intelligent customer (e.g. organic
chemicals with respect to tyres technology in automotive again) is of significance. That is
to say, the knowledge base of firms with respect to specific disciplines may also vary in
depth. Prencipe (2000) studied depth in the case of the evolution of the aero-engine control
system. His study focused on two dimensions of the knowledge bases of aero-engine
makers: the stages of the development process performed by engine makers, and the
different types of knowledge related to either the combination of control system’s6
components, or specific components (p. 898). His study showed the importance of
considering this additional dimension alongside breadth. However, the methodology
developed in that paper is tailored for the specific industry on which the paper focused.
In this study, we endeavour to develop a methodology based on publicly available data,
which is then replicable across sectors. Depth is studied by analysing the evolution of
specialisation across different typologies of research (i.e. basic, applied and development
oriented research). This refers to the complex, non-linear interdependencies that link the
scientific and technological domains. Core disciplines demand specifically extensive
investments that other disciplines do not because certain competence are needed to develop
and expand the knowledge base while different competence are needed to understand and
intelligently exploit the knowledge. In this sense, by interpreting depth as specialisation
across different types of research we try to operationalise the definition of depth put
forward in Wang and von Tunzelmann (2000), who talked about the degree of technical
difficulty entailed by, in our case, specific disciplines: the more complex (i.e. deep) a
discipline, the more it becomes necessary to focus on developments in that disciplines
across all the stages of research.
2.2. Why pharmaceuticals?
The pharmaceutical industry is a fast growing, rapidly changing sector that in the past three
decades has greatly increased both in its contribution to economic growth and its visibility
in the public policy arena. From our viewpoint, two empirical phenomena related to its
recent development are of particular interest. First, much of the growth of the industry is
due to endogenous processes of innovation (Orsenigo, 1989; Gambardella, 1995). While
changing regulatory frameworks and globalisation of the user markets certainly are playing
a role, the driving force of the industry is the emergence of new fields of scientific and
technological knowledge. Firms struggle to keep abreast of developments in a number of
specialised bodies of scientific and technological knowledge that on the one side provide
them with great innovative opportunities, while constantly challenging their established
ways of doing things. Increasingly specialised knowledge, and the capability to
continuously generate new scientific insights, have become the key to the competitive
advantage of the world’s leading pharmaceutical firms. Thus, the pharmaceutical industry
is characterised by the co-existence of heterogeneous bodies of scientific and technological
knowledge that need to be developed, coordinated and integrated. For this reason it is
important to consider the issue of the heterogeneity of its knowledge base, and the changing
breadth of firms’ capabilities.
Also, the industry is growing thanks to the co-existence of two mechanisms of growth.
First, the incumbents are growing larger and larger as a result of complex mergers and
acquisition (M&A). At the same time new, small, highly specialised firms are entering the
industry. Markets and hierarchies, the traditional ideal types of organisations considered by
economists and industry analysts, are complemented by increasingly complex webs of
relationships linking incumbents and new entrants involved in drug discovery. Networks of
innovating organisations have become the organisational cornerstone of the modern
pharmaceutical industry (Arora and Gambardella, 1994; Pisano, 1991). For example,
Orsenigo, Pammolli and Riccaboni (2001) have analysed in depth the organisation of7
innovative activities, looking at the characteristics of pharmaceutical R&D networks, and
their evolution over time. They pointed to the pivotal role played by large pharmaceutical
groups (and a very few first generation biotechnology firms) in designing and coordinating
these networks.
The heterogeneity of pharmaceutical firms’ knowledge bases is reflected in the fact that
development projects in this industry can last for over ten years, and involve a wide range
of activities. Not only is taking compounds from discovery to market a highly uncertain
process, but different tasks along the value chain also rely on very specific skills and
competences. Increasingly, pharmaceutical firms rely on Contract Research Organisations
(CROs) and Contract Manufacturing Organisations (CMOs) to undertake specific steps in
the value chain. At the same time, the company in charge of the overall development
project maintains sole responsibility as far as the regulatory authorities (e.g. the FDA) are
concerned. Issues of coordination and control are paramount. Firms involved in these
activities need to be able to perform basic research (to identify possible cures), clinical
investigation (to test them through the various stages of the trials), and clinical observation
(to finally test them in hospitals on patients, gather the data, feed them back to the
development team); and also to manage relationships with the relevant regulatory
authorities, to conduct negotiations with the various national health services, to maintain
links with doctors and hospitals, to organise the marketing and distribution effort, and so
on. All these activities must be carefully coordinated.
Does such coordination emerge out of arm’s length market relationships, or are some firms
in these networks ‘more equal than others’? And do they maintain the capabilities needed to
intervene should problems arise at any stage of this very deep and, nowadays, rather
disintegrated value chain? One way of approaching this question is to consider whether
large pharmaceutical firms are focusing their capabilities only on high-end development
activities, or are maintaining capabilities also at the level of clinical investigation and
clinical observation (stages in the value chain that are increasingly outsourced to contract
organisations). Hence, we will develop indicators of the depth of firms’ knowledge bases,
on the assumption that firms need a deep understanding of their value chain in order to be
able to act as integrators. Depth is measured by evaluating firms’ capabilities across
different types of research and development activities in any given discipline. Being able to
assess the depth of a firm’s knowledge base in a specific discipline would allow indirect
assessment of the ‘role’ that this firm actually plays in the value chain, i.e. whether it could,
in principle, act as an ‘integrator’.
In the following section the concepts of breadth and depth will be operationalised on the
basis of an original database of citations to non-patent references in the patent portfolio of
the 30 largest pharmaceuticals corporate groups.
2.  Methodology and data sources.
Patent documents must contain citations to other patents and references to a variety of other
documents such as papers, abstracts, conference proceedings, books, etc. (non-patent
references) as a legal requirement to supply a complete description of the state-of-the-art.
Citations limit the scope of the inventor’s claim to novelty and, in principle, they represent8
a link to previous innovations or existing knowledge upon which the inventor builds. On
the basis of this observation, during the nineties, a large body of literature spanning the
discipline of economics and science and technology studies has used information contained
in citations to ‘non patents documents’. Most of these works are based upon US Patent
Office (USPTO) data (see, among others, Narin and Olivastro, 1992; Narin, Hamilton and
Olivastro, 1997; Trajtenberg, Henderson and Jaffe, 1997), while very few use European
Patent Office (EPO) data (Verspagen, 1999; Malo and Geuna, 2000; Tijssen, 2002;
Verbeek et al., 2002a). The core issue addressed by these studies is the linkage between
science and technology. According to their disciplinary background the studies attempt to
trace the knowledge flow between science and innovation or to examine the science
dependence of specific technologies. Usually, particular attention is paid to the localisation
effect, i.e. is the linkage between innovation and scientific discovery affected by the
location of the research is carried out (regional, national, etc)? Non-patent references are
used as a proxy (a trace) for knowledge flow between different organisations. The inventor
citing an article is seen as the receiver of the knowledge produced by the author of the
article in another organisation (being it a university, a firm or a public research centre for
example).
Although a fair amount of interest has been generated by the results of the literature
referred to above, recent research warns about the risk of over-interpreting the existence of
non-patent references as proof of a direct link between cited papers and citing patents
(Meyer, 2000), and especially in the case of analysis at the micro level (Verbeek et al.,
2002b). Also, most citation studies are not able to precisely identify those citations chosen
by the inventor (Schmoch, 1993, briefly examines the citations made by inventors). The
patent document reports the citations as chosen by the examiner. Such citations can include
all, part or none of the citations originally chosen by the inventor. This problem may further
limit the interpretation of citations as being a direct link between the article and the patents.
Finally, it must be taken into account that, even if inventors’ citations were available, most
patent applications are filed with the help of large, and sophisticated, legal offices. Given
the increasing importance of the legal aspects of a patent (patent litigation increased
substantially in the 1990s), firms hire patent lawyers that are heavily involved in the
process of application. Citations may be chosen strategically and thus reflect the legal
strategy of the firm (aimed at minimising the risk of litigation, for example), rather than the
key linkages and networks on which the inventor relied.
In line with these observations, this paper proposes a less demanding interpretation of non-
patent references. In this work, citations are used as a proxy for some characteristics (i.e.
breadth and depth) of the knowledge bases upon which firms build. They hint at the bodies
of scientific and technological knowledge on which patents (and thus firms) rely, but, for
the current purposes, are not meant to imply any direct linkages between the inventors and
researchers active in those fields. They are not used to imply any specific network structure,
or localisation effects. They point to bodies of knowledge that the inventors (or the
examiners) thought relevant for the invention reported in the patent application.
In the context of our analysis the use of EPO patents might represent an advantage with
respect to using USPTO patents, because of the different legal requirements concerning the9
inclusion of citations. While applicants to the USPTO are obliged to cite all the documents
describing the state-of-the-art and failing to provide a comprehensive list might result in the
patent application being refused, for applications to the EPO providing such a list is
voluntary. As shown by Michel and Bettels (2001), this leads to a greater number of
citations in US patents (three-and-a-half times as many references to non-patent literature
compared to EPO patents) that may not be completely relevant to the patent being applied
for. EPO patents do not suffer from this problem and citations in these patents might better
reflect the company’s knowledge base.
Specifically, this paper examines the knowledge bases of the world’s largest
pharmaceutical groups (in term of sales in 1997). The 30 groups considered (see Table 1)
encompass some 3,500 subsidiaries in 1997. To derive indicators of their knowledge bases
we started from the patent portfolios of the groups. More precisely, the database used
includes the 33,127 patents filed with the EPO by the 30 largest corporate groups in the
pharmaceuticals industry during the period 1990-1997 (the 322 subsidiary patenting units
were consolidated with their parent companies in 1997 on the basis of the information in
‘Who Owns Whom’) as compiled by the Observatoire des Science and Technologie
(OST).
1 Table 1 shows the number of patent applications by group for the period under
consideration. Hoechst AG with 5,711 is the group with the largest number of patents,
followed by another German group, Bayer AG, with 5,534 patents. Four other groups:
Novartis Holding AG (3,373), Merck & Co. Inc. (1,769), Rhone-Poulenc SA (1,129) and
Zeneca Group Plc (1,067) each had over a thousand patent applications during the period.
The three Japanese groups Yamanouchi Pharmaceutical Co. Ltd (150), Sankyo Co. Ltd
(201), Shionogi & Co. Ltd (212) and Astra AB (292) had less than three hundred patents
each. Consistent with the evidence from the literature about the ‘home advantage’ (EC,
1997; EC, 2001), our database provides a good representation of EU group patenting
profiles, while it is under-representative of the patenting profiles of US and Japanese
corporate groups. This is a common bias in patent analysis: corporate groups tend to apply
for patents to their home country patent office. Usually inventors apply first in their home
country, then they apply for protection abroad for only a sub-set of the home country
patents (costs, penetration in the foreign market and other reasons being the reason for this).
{TABLE 1 ABOUT HERE}
From the 33,127 patents 41,931 non-patent references were extracted. Out of these, we
identified 25,996 citations (from 11,279 patents) to scientific articles included in the
expanded Science Citation Index of ISI (SCI). 6,502 SCI citations were to abstracts
included in the Chemical Abstracts and not to articles, thus they were excluded. On average
each patent cites 1.3 non-patent references and 0.6 scientific articles; however, the 8,474
patents that cited scientific papers from the SCI had, on average, 2.3 citations to articles.
2
We decided to focus only on the scientific publications included in the SCI database for
three reasons. First, the SCI database includes publications in peer-reviewed journals with
                                                            
1 See Filliatreau et al. 2002 for a description of the database. For access to the database see information on the
NewKInd web page http://www.researchineurope.org/newkind/Proj_doc.htm.
2 2,805 patents were excluded from the final database because either they had only citations to Chemical
Abstracts, or they had citations to journals not included in the CHI classification.10
international recognition; second, journals in the SCI database are classified in scientific
fields; and, third, journals in the SCI database can be linked via the  CHI journal
classification to four major categories of research -- e.g. applied technology, engineering
technological science, applied research, and basic research.
The SCI classification of journals in scientific fields used in this paper includes 132 fields
(see Appendix 1). We decided not to aggregate the 132 fields in broader scientific classes,
as it has been done in other studies, because we want to capture the detailed specialisation
process across groups. We also used a full count method, instead of a fractional one, in
counting the number of citations to a particular scientific field. A journal may be classified
under one or more scientific fields as it may publish research pertaining to one or several
disciplines. The full count method implies that we include all the scientific fields relevant
to a journal.
3 Given the focus of this paper, we assumed that if an article is published in a
journal classified under several scientific fields this is an indication that the article it will be
of as much interest to members of these fields as an article that is published in a single
discipline journal. The final database with scientific field classification includes 33,349
entries (see Table 1). As in the case of patent numbers, Hoechst AG is the group with the
largest number of scientific field citations while Yamanouchi Pharmaceutical Co. Ltd is the
group with the least.


























                                                            
3 The size of our database did not allow us to develop a better classification on the basis of analysis of article
titles.11
Figure 1 shows the result of the analysis of concentration structures of scientific fields. In
this figure, the number of scientific fields cited as a share of the total of citations is shown
for the complete population. There is a high level of concentration with a reduced number
of scientific fields accounting for a very significant share of the citations, and a long tail of
scientific fields with almost negligible amounts. The top six scientific fields in number of
citations account for about 58% of citations; they are, in order of importance: biochemistry
and molecular biology, multidisciplinary chemistry, pharmacology and pharmacy, organic
chemistry, medicinal chemistry and multidisciplinary sciences. The first 16 scientific fields
account for 80%. The long tail of the skewed distribution is composed of a large number of
scientific fields with a small number of citations; for example, more than 70 fields register
less than 20 citations each. The field of biochemistry and molecular biology is the only
scientific field present in the top six fields for all 30 groups. Multidisciplinary chemistry is
present in 28, pharmacology and pharmacy in 26, organic chemistry and medical chemistry
are both present in 22 groups and, finally, multidisciplinary sciences is within the top six
fields in 18 groups (see Table 2).
The CHI classification categorises all the SCI journals according to their research
orientation, more basic versus more applied, on four broad levels: applied technology,
engineering technological science, applied research, basic research. In the context of
biomedicine the four types of research levels are: clinical observation (Level 1), a mix of
clinical observation and clinical investigation (Level 2), clinical investigation (Level 3) and
basic research (Level 4) (Narin and Rozek, 1988). As Narin and Rozek (1988) state, Level
1 is typified by the Journal of the American Medical Association, Level 2, by The New
England Journal of Medicine, Level 3, by the Journal of Clinical Investigation, and Level
4, by the Journal of Biological Chemistry.
Notwithstanding the limitations to relying on a classification of journals and not articles,
this does allow the citations to scientific journals to be classified in research typologies.
Using the 1999 CHI classification we categorised the 18,773 references to articles in the
four CHI levels (we excluded from the analysis the 721 references to social science journals
and to journals not included in the 1999 CHI classification). About 8% of the citations are
to applied journals classified in the first two levels, 30% are to journals devoted to clinical
investigation and the remaining 61% of references are to basic research journals. The strong
reliance on basic research suggests a reclassification of the CHI levels into two major
typologies of research: the first including both clinical observation and clinical
investigation (levels 1, 2 and 3), the second accounting for the basic research component.
This classification will be used in the next section for analysis of the depth of the
knowledge bases of corporate groups.
3.  The knowledge bases of the world’s largest pharmaceutical groups
In this section we analyse a set of indicators of breadth and depth of the knowledge bases of
the 30 groups. First, we start by developing indicators of the breadth of the knowledge base
over the whole period, followed by an analysis of its evolution. Second, we develop two
indicators of the depth of the knowledge base that try to capture the presence of integration
capabilities in the group at field level.12
3.1 Breadth of the knowledge base
A preliminary exploration of groups’ specialisation portfolios was made. We found that,
when focusing on the scientific fields in which corporate groups specialise, there is a
greater variety than that present in the total population. The profiles of different groups are
heterogeneous and depend on the activities in which they engage and the markets they
target. Table 2 presents a summary of the individual specialisation profiles of different
corporate groups; it includes the top six scientific fields by number of citations, the number
of scientific fields with at least ten citations (over the whole period) and the scientific fields
that have a Relative Specialisation Index (RSI) > 0.3 (those fields of core specialisation for
which a given group has a share in the group’s total citations which is at least the double of
that of the field’s aggregated share in the citations of the total population – see formula
below). Finally, we define distinctive scientific specialisation as those fields among the top
six for which the corporate group has a RSI > 0.3. On average, the groups have at least 10
citations across 18 scientific fields. Hoechst AG (43), Novartis (39) and Bayer AG (35) are
active in more than 35 fields, while Teijin Ltd (3), Yamanouchi Pharmaceuticals Co. Ltd
(4), Sankyo Co. (5) and Johnson & Johnson Inc. (5) have less than 6 fields with at least 10
citations over the whole period.
{TABLE 2 ABOUT HERE}
Although the top six fields across groups tend to be quite similar, some important
differences appear both in terms of field concentration and field specialisation. A few
corporate groups stand out in terms of their focus on certain scientific fields. For example,
the top six scientific fields for Baxter International are biochemistry and molecular biology,
cardiac and cardiovascular systems, haematology, immunology, medicine (research and
experimental), and peripheral vascular diseases. Also, Baxter International has very
strongly defined distinctive scientific specialisations, with only four fields with RSI > 0.3
all of which are in its top six fields. This specialisation profile seems to point to a specific
market focus for Baxter’s innovative activities. Although most groups do not show such a
focused specialisation profile, nevertheless a few specific scientific fields, relatively
important in their citation portfolios, can be detected. For example, Monsanto has a
distinctive scientific specialisation in plant sciences and organic chemistry, these being
among the top six fields with an RSI of respectively 0.77 and 0.36. Similarly, Zeneca,
though with a large number of active scientific fields, has a clear specialisation profile with
an important distinctive scientific specialisation in plant science (top six and RSI=0.8) and
core scientific specialisation in agronomy and biology. At the other extreme, Bayer AG,
Hoechst AG and Novartis, with large citations portfolios, show a more diversified pattern
of scientific specialisation making it quite difficult to characterise in a clear-cut manner
their scientific profile in term of specific competences.
From the results of this preliminary analysis, it is clear that the 30 groups rely, at least in
part, on different knowledge bases (for example both Bayer AG and Novartis have very
broad specialisation profiles yet they exhibit different  distinctive specialisations in,
respectively, polymer sciences and plant sciences). However, analysing the citations across
the whole period, provides only limited information on the breadth of the knowledge bases13
of different corporate groups. In order to overcome this limitation, we focus on the
evolution of the breadth of the knowledge bases over time.
To do this, we examined the citation portfolios of the groups in the two sub-periods: 1990-
92 and 1995-97. We compared these two periods with the aim of examining trends in the
evolution of the breadth of the knowledge bases. Two approaches were adopted. First, we
looked at which fields each group was active in during both periods (persistency), and
which fields each group cited at the end of the period only (entry), or at the beginning only
(exit). Also, measures of similarity and concentration by sub-period were calculated for
each group citation profile. Second, we calculated the Relative Specialisation Indexes for
the two periods and examined their correlation across periods. This approach allowed us to
characterise the breadth of the knowledge base of the groups both in term of the presence of
citations in a specific field and of changes in scientific specialisation.
Table 3 presents the changes in the breadth of the knowledge bases of the corporate groups
in terms of entry, exit and persistence in the citations to scientific fields. Table 3 presents
the number of scientific fields in which each group was active in the second sub-period but
not the first (entry: number of new fields in 1995-97);
4 the number of fields in which the
group no longer has citations (exit: number of fields exiting); and finally the number of
fields in which the group cites in both periods (number of persistent fields in the two sub-
periods). To examine the changes in the breadth of the knowledge base of a group in terms
of the number scientific fields in which it is active, we used a measure of similarity
originally derived by Jaffe (1986). In our case the indicator (Sk) provides a measure of the
scientific distance between the breadth of the specialisation profile of each group in the two
sub-periods. The distance (i.e. variation in breadth) in scientific specialisation across time
can be approximated by an un-centred correlation coefficient of the vectors (fi and fj) of
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where k = 1…30; corporate groups
and i = period 1990-1992; j = period 1995-1997
This similarity measure is bounded between 0 and 1, and the greater the degree of similarity
between the breadth of the groups in the two periods the closer it is to unity.
                                                            
4 ‘Active’ indicates that a group has cited at least 10 times articles classified in a particular scientific field in a
given sub-period. It is worth pointing out that this means that the number of active fields throughout the
period is in general higher than the sum of the number of persistent, exiting, and new fields. There might be in
fact fields with more than 10 citations between 1990-97 but those citations are uniformly spread across the
whole period and they never reach the threshold level in any one particular sub-period.14
{TABLE 3 ABOUT HERE}
In terms of similarity, most groups show a high level of similarity (average of 0.75). 21
groups have a similarity index above 0.5; of these 14 have an index above 0.8 and 7 above
0.9. However, four groups do not have any overlap among the fields cited at the beginning
and at the end of the period (these are the same groups with small number of citations, that
in Table 2 have less than 6 fields with at least 10 citations), and five groups have a
similarity index lower than or equal to 0.5. The table shows a weak trend toward increasing
the range of fields in groups’ citation portfolios. Taking the arithmetic average of the
differences between entry and exit, the result is an average ‘net entry’ for two fields (2.23).
Adjusting this average by the number of fields in which groups are active throughout the
period (i.e. calculating the ratio between net entry and total number of cited fields over the
entire period, then taking the arithmetic average), one gets a positive increase in breadth
(0.12).
Although not reported in the table, we measured the concentration of the scientific
specialisation of the groups using the Herfindhal index. The index for each group was
calculated for the two sub periods and for the whole period. Most groups show very low
levels of concentration (< 1,000) of citations across scientific fields. Over time, no clear
trend toward increasing or decreasing concentration emerges.
Given these results we proceeded to the examination of the changes in the specialisation
profiles of the groups. To do this we calculated the symmetric Relative Specialisation Index
(RSI) for all groups and for all fields for the initial period (1990-1992) and the final one
(1995-1997).
5 The symmetric Relative Specialisation Index (RSI) is obtained standardising
the activity index (AI), which is defined as the share of citations in a given scientific field
in the citation portofolio of a given corporate group, relative to the share of citations in a
given scientific field, for all corporate groups, in the overall sample of citations.
6 The RSI
index indicates whether a firm has a higher-than-average activity in a scientific field (RSI >

























where p = number of cited publications,  i = 1….n = number of scientific fields = 132 and
                                                            
5 Due to the problem of small numbers in cells, the analysis of the changes in the specialisation profile of
corporate groups is based upon scientific fields with at least 10 citations in the considered periods at the group
level.
6 The two totals for the group and for the overall sample include citations in all scientific fields regardless of
the specified threshold level of the 10 citations in the period under analysis.15
j = 1…m = number of corporate groups = 30.
The aim here is to determine whether we can see persistence in the structure of
specialisation. We first focus on entry and exit into new scientific fields. Table 4 builds
upon Table 3 focusing on the fields which groups have ceased or have begun citing, whose
RSI is above 0.3. In other words, we look at changes in the groups’ fields of core
specialisation.
{TABLE 4 ABOUT HERE}
Again, cross-group heterogeneity emerges quite visibly. However, some trends are also
observable. Of the 30 groups considered, 14 show no exit from the fields of  core
specialisation (i.e. those with an RSI above 0.3). Seven groups show the loss of only one
field of core specialisation. Five groups (Bristol Myers Squibb, Glaxo Wellcome, Hoechst
AG, Novartis and Sanofi-Synthelabo) exhibit a fairly big change in core specialisation with
four or more fields exiting the core. Conversely, on the entry side, only five groups show
no new entry in the areas of core specialisation, 8 groups have at least one new entry, and 7
groups exhibit at least four new fields with an RSI above 0.3. Bristol Myers Squibb,
Hoechst AG and Novartis appear to be the most active groups in terms of both entry and
exit. In some cases, we can distinguish a few clear patterns. For example, it seems clear that
Abbott Laboratories is moving into the bio-pharma area: new fields of core specialisation
include biochemistry research methods, biotechnology, genetics and heredity,
microbiology, and virology. In other cases the patterns are less clear. For example, Bayer
seems to be moving into traditional fields such as analytical chemistry, physical chemistry,
and agronomy, but also optics and radiology. Overall then, pharmaceutical groups appear to
be more ‘active’ on the entry than on the exit side. This is consistent with the argument that
the emergence of new fields of useful research leads to an increase in the breadth of the
knowledge base.
Table 4 focuses on the fields of specialisation that entered or exited the core specialisation
of the groups studied. Table 5 focuses, instead, on changes in the fields that persistently
appear as part of the specialisation profile of the group. To determine the relationships
between specialisation structures during the period 1990-92 and the period 1995-97, we
calculated the Pearson and Spearman correlation coefficients between RSIs in 1990-92 and
1995-97 by corporate groups. Correlation coefficients and their levels of significance are
presented in Table 5.
{TABLE 5 ABOUT HERE}
First of all, only 15 corporate groups have at least 7 scientific fields of persistent
specialisation –i.e. those fields in which the group was active in both sub-periods. For these
15 groups
7, the Pearson and Spearman coefficients deliver consistent results: the
coefficients, while different in value, do not affect the ranking of groups. Of the 15 groups
considered in Table 5, only eight show significant correlation across RSIs in the two sub-
periods. Of the eight groups for which we have significant results, Bayer appears to be the
                                                            
7 The groups with less than 7 fields of persistent specialisation were not included in this analysis because the
correlation coefficients tend to be less reliable with few observations.16
one with the most stable specialisation profile (but this result should be read in conjunction
with the data in Tables 3 and 4, which show the extent to which Bayer is entering new
fields). Merck & Co. appears instead as the group characterised by the sharpest changes in
specialisation profile. In particular, it can be seen from Table 4 that Merck has entered the
fields of cellular biology and histology, biochemical research and virology. Unlike Merck,
Abbot Laboratories appears to have added the bio-pharma fields highlighted above (see
discussion of Table 4 above) to a more stable specialisation profile.
Overall the analysis of the knowledge breadth of the largest pharmaceutical groups reveals
a high level of group-level heterogeneity in the field of active involvement and in the fields
of specialisation when considering either the entire period or the changes from the starting
to the end. Particularly interesting are the results of the analysis of change in the knowledge
bases. Though groups have a high level of similarity in their portfolio of citations at the
starting and end of the 1990s, we found some evidence of a weak but positive increase in
their breadth, a significant entry in new fields of  core specialisation, and a low level of
persistent specialisation for the stable fields. The analysis allows one to highlight a few
clear patterns at the level of the individual group. For example, while Abbott Laboratories
is specialising in bio-pharma, Bayer seems to maintain, and actually reinforcing, its
specialisation in traditional fields.
4.2 Depth of the knowledge base
Evaluating firm capabilities across different types of research and development activities
gives an indicator of the depth of the capabilities maintained by an organisation in any
given discipline. The intuition behind this analysis is that if a corporate group has a positive
specialisation in a given scientific fields for each typology of research (e.g. it has a positive
specialisation both in clinical observation/investigation and in basic research in the field of
pharmacology and pharmacy) it has a knowledge base of greater depth in that scientific
field compared to the other groups because its citation profile points to higher involvement
in that discipline across typologies of research. In other words, the group is not only active
in the more applied part of the research (clinical observation and investigation), but it also
has competences in the area of basic research.
In order to analyse the integration of research across categories (depth of knowledge base),
we calculated two indicators of integration (or depth) based on the symmetric RSI. The first
indicator uses an RSI index calculated for each pair of scientific field and typology of
research with at least 5 citations. The integration index is given by the ratio between the
numbers of pairs of scientific fields and typology of research which show a positive
specialisation in both CHI levels and the number of scientific fields of positive
specialisation. So, for example, let us consider the case of ‘neurosciences’. In order to be
able to say that a company is ‘integrated’ in neurosciences (i.e. it has a ‘deep’
understanding of this discipline), we calculate the RSI for that company on the basis of the
citations to neurosciences journals that focus on basic research. Then, we calculate the RSI
in neurosciences for the same company on the basis of the citations to neurosciences
journals that focus on clinical observation and investigation. If the company considered is
relatively specialised (i.e. RSI > 0.3) in both types of research, within neurosciences, than
we say that this company is ‘integrated’ in neurosciences, and we add ‘one’ to the
numerator. The numerator of the indicator then says in how many disciplines a firm is17
relatively specialised in both categories of research. The denominator controls for the size
of the groups’ citation portfolios. This integration measure is derived using the formula
below and it varies between 0 and 1. It is 0 when the group considered does not exhibit any
overlap between the two types of research. It is 1 when the group considered is fully
integrated across all types of research in all the fields in which it exhibits positive
specialisation (Brusoni and Geuna, 2003).
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The second integration index provides a less restrictive measure of the depth of the
knowledge base. Instead of requiring a positive specialisation for the pair of scientific field
and typology of research, it accounts only for the fact that the corporate group is active (pik
number of cited publications) in both levels of research in a given field (with at least 5
citations) with a positive specialisation. Let us use again the example of neurosciences. In
order to consider a firm integrated in neurosciences, we first calculate the RSI for this filed.
If the firm is relatively specialised in neurosciences (i.e. RSI > 0.3), we check whether this
firm’s patents cite journals focused on both types of research (i.e. basic research and
clinical observation and investigation). If so, we consider this firms integrated in
neurosciences. We do not require the firm to be relatively specialised in both types of
research (within the field of neurosciences). We just require the firm to cite neurosciences
publications that focus on both types of research. If the firm’s patents cite journals in only
one of the research categories, then it is not integrated in neurosciences. As shown in the
following formula the denominator used is the one used in the  INT1 measure. This
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Table 6 presents the two integration indicators and the scientific fields in which each
corporate group is integrated. Though INT2 is less restrictive than INT1 in 97% of the
cases both indicators found the same scientific field to be integrated. INT2 has slightly
higher values and it identifies more scientific fields as being integrated. The following
analysis will be mainly based upon the indicator INT1. Only three corporate groups have
INT1 ‡ 0.2, they are: Eli Lilly and Co., Rhone-Poulenc SA and SmithKline Beecham Plc.
Abbott Laboratories and American Home Products also have high values. Eli Lilly and Co.
(0.25) has a positive specialisation across research typologies in 5 fields: biotechnology and
applied microbiology, medicinal chemistry, research and experimental medicine,
neurosciences, pharmacology and pharmacy. Rhone-Poulenc SA is integrated in
biochemistry and molecular biology, biotechnology and applied microbiology, genetics and
heredity, immunology, microbiology and neurosciences. SmithKline Beecham Plc is
integrated in biochemistry and molecular biology, microbiology, neurosciences,
pharmacology and pharmacy. Abbott Laboratories exhibits a fairly clear profile in bio-
pharmaceuticals. The integrated fields are biochemical research methods, biotechnology
and applied microbiology, microbiology and virology. The extent of overlap with Table 4 is
remarkable: the integrated fields are all fields in which this group was not active in the
period 1990-92. Monsanto is integrated in plant sciences only, which reflects the strategic
focus of this group over the period considered. Moreover, Hoechst AG and Bayer are
integrated only in material sciences and multidisciplinary chemistry respectively, reflecting
that these groups (in the period considered) were still behaving as traditional ‘chemical’
companies. Overall, the fields related to the new bio-pharma trajectory seem to be quite
likely to be developed in an integrated manner. In other words, the data in Table 6 point to
the fact that those groups that have entered on this research trajectory, have done so by
quickly developing strong competencies across research typologies in the relevant fields.
The data capture the delay of the German groups, and hints at the possibility that such delay
is characteristic only of the German groups, rather than all the EU countries.19
{TABLE 6 ABOUT HERE}
Finally, and from a methodological perspective, we should point out that the depth
indicator employed in this section makes it possible to discriminate between groups in a
more straightforward way than the breadth indicators calculated in Section 4.1.
Specifically, the depth indicator is not biased by the size of the patenting activity of a
group, and it provides a better proxy for the strategic research orientation of the group; for
example, Bayer AG, Hoechst AG and Novartis have a very high number of patents and
citations, but they have only very few integrated fields, with the German groups focused on
traditional chemicals and the Swiss group integrated in the bio-tech, microbiology area.
4.  Inventors’ citations versus examiner’s citations, a methodological test
In this section we investigate the robustness of the indicators of breadth and depth of
groups’ knowledge bases calculated above. We focus on the difference in the citation
sources; as we pointed out before, the list of references to patent and non-patent literature is
initially proposed by the applicant, but the final decision about which documents are cited
in an application lies ultimately with the patent examiner, who might decide to accept those
included by the applicant or add new references.
In this study we were able to discriminate between the citations listed by the examiner and
those initially proposed by the applicant and accepted by the patent examiner, using the
search report completed by the patent examiner during the screening of the technically
relevant literature. The EPO’s search reports contain various characters relating to each
citation indicating the categories of the citation, which grade the cited document according
to its relevance.
8 In addition, when the citation attached by the examiner is the same as that
proposed by the applicant, the examiner will add the letter ‘D’ to the category of citation.
From our initial database we extracted all the citations to non-patent references proposed by
the applicant and accepted by the examiner and a random sample of citations, for which the
source is unknown (this sample reflects the data normally used in citation analysis). We
were able to identify 2,843 citations to non-patent literature included by the applicant,
which correspond to 4,436 observations with scientific field classification. The random
sample contains 2,498 citations, which leads to 4,054 entries with scientific field
classification. The two samples are also similar in terms of the number of patents: the
sample containing applicant citations has 1,987 patents while the one with random citations
has 2,114 patents. Using the two samples we can verify the validity of a non-patent
references citations analysis that does not distinguish the source of the citations as we have
done in the previous sections.
9
                                                            
8 For example the category X citation indicates a document of particular relevance; the claimed invention
cannot be considered novel and/or inventive in view of the citation.
9 Due to the very small number of citations in the two samples of citations considered we could not develop a
significant test for the integration measure.20
Although not reported, we calculated the RSI index for each company and for each
scientific field with at least 5 citations using data from both samples of citations over the
period 1990-1997.
10 The two sets of RSI indexes have almost 60% of scientific fields in
common, which implies that the portfolio of citations added by the applicant is to some
extent different in its scientific focus from the random one. To test if the two sets of RSI
values for the scientific fields in common are statistically different, we ran the following
regression:
e b a + + + = dummygroup RSI RSI a r
where RSIr  is calculated using citations from the random sample, RSIa is calculated using
the applicant sample, and dummygroup are dummy variables for each corporate group to
control for firms specificities.
The results of the regression show that there is strong positive and significant partial
correlation between the two sets of RSI indexes (b equals to 0.87 significant at 1% level),
once controlled for firms’ specificities. We can therefore conclude that the common
practice of using citations to non-patent literature without distinguishing their source can
lead to some differences in terms of fields of specialisation, although for the common fields
the value of the RSIs is not substantially different.
5.  Conclusions
This paper has proposed indicators to capture the evolution of the knowledge base of the
world’s largest pharmaceutical groups by sales. The analysis of such evolution has focussed
on two dimensions: breadth and depth. Overall the analysis of the knowledge breadth of the
largest pharmaceutical firms reveals high group-level heterogeneity in terms of
specialisation profiles. We found some evidence of a weak but positive increase in groups’
breadth, a significant entry in new fields of core specialisation, and a low level of persistent
specialisation for the stable fields. The analysis allows a few clear patterns at the level of
individual groups to be highlighted. For example, while Abbott Laboratories is specialising
in bio-pharma, Bayer seems to maintain, and actually be reinforcing, its specialisation in
traditional fields.
Alongside traditional indicators of specialisation, we have proposed two new indicators of
knowledge depth (or integration). We have argued that this additional dimension is
fundamental to capture recent changes in the processes of knowledge production
highlighted so far through case study research. In terms of depth, only three groups appear
to be integrated in about a quarter of the fields in which they are positively specialised.
Also, we found evidence of substantial group-level heterogeneity in terms of integration,
with, in a few cases, the integration clearly reflecting the strategic focus of the group in
                                                            
10 As in the first part of the analysis we use a threshold level of 5 citations per scientific field to avoid the
problem of small numbers. In the formula for RSI we use the totals for the group and for the overall sample
including citations in all scientific fields regardless of the specified threshold level.21
question (e.g. Monsanto in plant sciences). Finally, it appears that those groups that have
entered the bio-pharma trajectory, seems to have done so by quickly developing strong
competencies across research typologies in the relevant fields (e.g. Abbott Laboratories).
The empirical results of this paper seem to confirm the findings of recent research on the
organisation of knowledge production in the firm, and raise a few more questions. First of
all, it is important to observe the clear presence of group-level heterogeneity, in terms of
both breadth and depth. We found some evidence of the fact that the results highlighted by
the indicators of breadth and depth are consistent with what we know about group-level
strategies and market focus (e.g. in the period studied, German firms were still specialised
only in traditional chemical fields). Second, the indicator of depth seems to capture the
increasing specialisation of both US and European firms (except the German groups) in
fields related to bio-pharmaceuticals. The fact that these groups were developing highly
integrated capabilities while at the same time entering a large number of alliances and joint
R&D projects with specialised bio-technology firms, hints at the fact that these ‘knowledge
integrated’ groups might play a co-ordinating role similar to that played by ‘systems
integrators’ in other industries. This point seems to be consistent with the analysis of
Orsenigo, Pammolli and Riccaboni (2001), which looked at the evolution of R&D networks
in the bio-pharmaceutical area. This paper has provided a first look at complementary
evidence focussing on one specific node of these networks.
This type of analysis needs to be pushed forward in a number of directions. Three would
seem particularly promising. First, we need to study in more detail the relationship between
the specialisation patterns identified (in terms of both breadth and depth) and the
technology and product strategy of the groups. While some clear connection emerges
(Abbot Laboratories entry in bio-pharma, Monsanto’s specialisation in plant sciences, the
emphasis on traditional chemistry fields of the German groups) other groups do not show
clear patterns. Second, the indicators developed here (and particularly that of integration)
need to be probed against indicators of innovative performance. Can these indicators help
to distinguish between innovative and non-innovative firms? Third, on a methodological
note, as the use of patent citations increases, the reliability of such indicators must be
questioned and, particularly in relation to what empirical phenomena they really capture.
For example, the issue of identifying possible differences between the results achieved
using the inventors’ original citations, as opposed to the citations as reported by the patent
examiner need serious consideration in order to validate these, and other, indicators based
upon the use of patent citations.22
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Table 1: Patent applications and citations in the period 1990-1997, by corporate
groups
Pharmaceuticals groups Country Patents SCI-fields Citations
Abbott Laboratories Inc. US 865 968
American Home Products Corporation US 939 1661
Astra AB Sweden 292 418
Baxter International Inc. US 630 247
Bayer AG Germany 5 534 1904
Bristol-Myers Squibb Co. US 902 1335
Eli Lilly and Co Inc US 944 1666
Glaxo Wellcome PLC UK 353 1315
Hoechst AG Germany 5 711 4112
Hoffmann-La Roche Inc. Switzerland 990 1862
Johnson & Johnson Inc. US 815 200
Kyowa Hakko Kogyo Co. Ltd Japan 316 398
Merck & Co. US 1 769 2483
Merck Patent GMBH Germany 644 478
Monsanto US 628 457
Novartis International AG Switzerland 3 373 3329
Pfizer Inc. US 954 940
Pharmacia US 810 1578
Rhone-Poulenc SA France 1 129 1535
Sankyo Co. Ltd Japan 201 191
Sanofi-Synthelabo Inc. France 465 754
Schering AG Germany 589 682
Schering-Plough Corporation US 400 653
Shionogi & Co. Ltd Japan 212 302
SmithKline Beecham PLC UK 862 1342
Takeda Chemical Industries Ltd Japan 715 691
Teijin Ltd Japan 353 137
Warner-Lambert Co. Inc. US 515 549
Yamanouchi Pharmaceutical Co. Ltd Japan 150 100
Zeneca Group PLC UK 1 067 1062
Total 33,127 33,34926
Table 2: Top six scientific fields and core scientific fields for 30 corporate groups.




Abbott Laboratories CQ , DX, DY, NI, QA, RO 20 QA, CO, EA, JY, NN, PW, ZE
American Home Products CQ, DR, DY, NI, RO, TU 26 DR, NI, AM, CU, FQ, MA, YA, YP, ZC, ZE
Astra AB CQ, DX, DY, EE, NI, TU 10 NN, QU
Baxter International Inc. CQ, DQ, MA, NI, QA, ZD 6 DQ, MA, QA, ZD
Bayer AG CQ, DX, DY, EE, TU, UY 35 EE, UY, AM, DW, EA, EC, EI, II, IQ, IY,
OA, PM, PW, SY, UB, UE, VY, YE
Bristol-Myers Squibb Co. CQ, DX, DY, NI, RO, TU 23 DM, DQ, FQ, PY, VE, WE, ZD
Eli Lilly and Company CQ, DX, DY, EE, RO, TU 22 CU, IA, PY, RU, SD, VE
Glaxo Wellcome PLC CQ, DX, DY, NI, RO, TU 21 DM, NN, PY
Hoechst AG CQ, DX, DY, EE, RO, TU 43 CU, EC, EI, II, IY, PK, PM, PW, UB, UK,
UY, WE, YA, YP, ZD
Hoffmann-La Roche Inc. CQ, DR, DY, EE, RO, TU 25 RO, CO, CU, FQ, MA,
Johnson & Johnson CQ, DX, DY, EE, TU 5 TU
Kyowa Hakko Kogyo Co. Ltd CQ, DX, DY, EE, QU, TU 11 QU, DB, DM
Merck & Co. CQ, DX, DY, EE, RO, TU 27 IA, KI, TI, VY
Merck Patent GMBH CQ, DB, DX, DY, EE, TU 9 DB, EA, FI
Monsanto CQ, DE, DR, DY, EE, RO 12 DE, EE, AM, DW, UY
Novartis International AG CQ, DE, DY, EE, RO, TU 39 DE, AM, DW, EA, EC, EI, II, IY, JY, KM,
MU PM, UY, VE, YA, YP, ZD
Pfizer Inc. CQ, DX, DY, EE, NI, TU 15 DX, TU, DX, NN, RT, TU, VE, ZC
Pharmacia & Upjohn Co. CQ, DX, DY, EE, RO, TU 27 AD, CO, DW, EA, GA, IA, JY, PY, SA
Rhone-Poulenc CQ, DY, EE, NI, RO, TU 27 DW, KM, MA, NN, RT, RU, ZD
Sankyo Co. Ltd CQ, DX, DY, EE, TU 5
Sanofi Synthelabo Inc. CQ, DX, DY, EE, KM, TU 17 KM, DE, DQ, JY, RU
Schering AG CQ, DX, DY, EE, NI, TU 15 IA, MA, PY, RT, RU, SD, VY
Schering-Plough Corporation CQ, DY, EE, NI, RO, TU 14 NI, MA, QA, ZE
Shinogi & Co. CQ, DA, DX, DY, EE, TU 9 DA
SmithKline Beecham PLC CQ, DX, DY, QU, RO, TU 19 QU, KI, PY, RT, YO
Takeda Chemical Industries Ltd CQ, DA, DX, DY, RO, TU 15 DA, DQ, IA
Teijin Ltd CQ, MA, RO 3 CQ, MA, RO
Warner-Lambert Ltd CQ, DX, DY, EE, RU, TU 8 DX, RU, TU, DQ
Yamanouchi Pharmaceutical Co. Ltd CQ, DX, DY, TU 4 DX, DY, TU
Zeneca CQ, DE, DX, DY, EE, TU 15 DE, AM, CU
See Appendix 1 for scientific fields codes.
No Fields: Number of scientific fields with at least 10 citations.
Bold Underlined are the fields of positive specialisation that are also within the top six fields, we consider
these the fields of distinctive specialisation.27


















Abbott Laboratories 20 5 1 8 0.81
American Home Products 26 4 1 14 0.91
Astra AB 10 5 1 1 0.42
Baxter International Inc. 6 1 1 0
Bayer AG 35 10 1 7 0.99
Bristol-Myers Squibb Co. 23 3 8 9 0.62
Eli Lilly and Company 22 8 2 9 0.83
Glaxo Wellcome PLC 21 2 4 8 0.83
Hoechst AG 43 5 7 21 0.91
Hoffmann-La Roche Inc. 25 4 2 13 0.82
Johnson & Johnson 5 4 0 0
Kyowa Hakko Kogyo Co. Ltd 11 2 2 3 0.69
Merck & Co. 27 5 0 13 0.82
Merck Patent GMBH 9 1 1 5 0.87
Monsanto 12 2 0 4 0.42
Novartis International AG 39 11 5 18 0.94
Pfizer Inc. 15 5 0 5 0.94
Pharmacia & Upjohn Co. 27 4 3 12 0.98
Rhone-Poulenc SA 27 12 0 9 0.37
Sankyo Co. Ltd 5 0 2 1 0.50
Sanofi Synthelabo Inc. 17 2 5 5 0.75
Schering AG 15 4 1 5 0.96
Schering-Plough Corporation 14 3 0 7 0.77
Shinogi & Co. 9 2 0 0 0.41




0 2 7 0.60
Teijin Ltd 3 0 1 0





Zeneca 15 2 0 8 0.89
No Active Fields: Number of scientific fields with at least 10 citations.28
Table 4: Entry and exit in core specialisation fields, by corporate groups
Corporate Group Fields exiting New fields
Abbott Laboratories PW CO, DB, KM, QU ZE
American Home Products IA AM, ZE
Astra AB NI
Baxter International Inc. MA
Bayer AG AM, EA, EI, PW, SY, VY
Bristol-Myers Squibb Co. DB, DQ, PY, QU, RU, VE, WE, ZD DM, FQ
Eli Lilly and Co. KM, QU DM, IA, PY, RU, SD, VE
Glaxo Wellcome PLC FQ, KM, NN DM
Hoechst AG II, UB, UK, ZD, ZE CU, DW, EA, EI
Hoffmann-La Roche Inc. CO DM, MA
Johnson & Johnson TU
Kyowa Hakko Kogyo Co. Ltd NI, QU
Merck & Co. CO, FQ, ZE
Merck Patent GMBH FI DB
Monsanto AM, DB
Novartis International AG IA, PY, RT, RU, VE CO, DQ, DW, EA, EI, II, MA, YP, ZD
Pfizer Inc. DM, NN, RU
Pharmacia & Upjohn Co. GA, QA, SA EA, IA
Rhone-Poulenc DB, DQ, FQ, MA, NN, QA, RU, ZD, ZE
Sankyo Co. Ltd DX
Sanofi Synthelabo Inc. DB, DE, JY, KM, QU QA, RU
Schering AG RU IA, SD, VY
Schering-Plough Corporation QA, ZE
Shinogi & Co. EE
SmithKline Beecham PLC DA, KM, PY, QU






Only scientific fields with RSI>0.329
Table 5: Correlation between RSI-end of period on RSI-beginning of period, by
corporate group.
Corporate Group Pearson coefficient Spearman rank coefficient
Abbott Laboratories Inc. 0.883** 0.810*
American Home Products 0.899** 0.745**
Bayer AG 0.972** 1.00**
Bristol-Myers Squibb Co. 0.513 0.517
Eli Lilly and Co. 0.042 0.183
Glaxo Wellcome PLC 0.657 0.548
Hoechst AG 0.621** 0.657**
Hoffmann-La Roche Inc. 0.557* 0.571*
Merck & Co. 0.575* 0.264*
Novartis International AG 0.652** 0.682**
Pharmacia & Upjohn Co. 0.897** 0.678*
Rhone-Poulenc 0.189 0.283
Schering-Plough Corporation 0.745 0.464
Takeda Chemical Industries Ltd 0.505 0.036
Zeneca 0.672 0.31
Only included corporate groups with at least 7 fields of persistent specialisation30
Table 6: Integration indicators (INT1 & INT2) and code of fields integrated for each
corporate group
Corporate Groups INT1 Fields INT2 Fields
Abbott Laboratories 0.18 CO, DB, QU, ZE 0.18 CO, DB, QU, ZE
American Home Products 0.16 CQ, IA, NI, QU 0.16 CQ, IA, NI, QU
Astra AB 0.09 QU 0.18 DY, QU
Baxter International Inc. - -
Bayer AG 0.03 DY 0.03 DY
Bristol-Myers Squibb Co. 0.04 NI 0.08 NI, RU
Eli Lilly and Co. 0.25 DB, DX, QA, RU, TU 0.3 DB, DX, DY, QA, RU, TU
Glaxo Wellcome PLC 0.11 DB, QA 0.16 DY, QA, RU
Hoechst AG 0.03 PM 0.08 DY, IA, PM
Hoffmann-La Roche Inc. 0.08 CQ, IA 0.13 CQ, IA, KM
Johnson & Johnson - -
Kyowa Hakko Kogyo Co. Ltd 0.09 DY 0.09 TU
Merck & Co. 0.2 CQ, IA, QU, TU 0.25 CO, IA, QU, RU, TU,
Merck Patent GMBH 0.12 DB, DY 0.12 DB, DY
Monsanto 0.11 DE 0.11 DE
Novartis International AG 0.05 DB, DE 0.11 CQ, DB, DE, QU
Pfizer Inc 0.13 DY, RU 0.13 DY, RU
Pharmacia & Upjohn Co. 0.08 CQ, DB 0.08 CQ, DB
Rhone-Poulenc SA 0.27 CQ, DB, KM, NI, QU, RU 0.27 CQ, DB, KM, NI, QU, RU
Sankyo Co. Ltd 0.14 DY 0.14 DY
Sanofi Synthelabo Inc. 0.05 RU 0.11 DY, RU
Schering AG 0.15 DY, IA 0.15 DY, IA
Schering–Plough Corporation - -
Shinogi & Co. - 0.1 DY
SmithKline Beecham PLC 0.23 CQ, QU, RU, TU 0.22 CQ, QU, RU, TU
Takeda Chemical Industries Ltd - 0.05 DY
Teijin Ltd - -
Warner-Lambert Ltd 0.1 DY 0.1 DY
Yamanouchi Pharmaceutical Co. Ltd - -
Zeneca 0.07 DB 0.14 DB, Y31
Appendix 1: Scientific cat codes
Code Discipline
AA acoustics
AC automation and control systems









CO biochemical research methods




DB biotech and applied microbiology
DE plant sciences
DM oncology
DQ cardiac and cardiovascular systems
DR cell biology






EC chemistry, inorganic and nuclear
EE chemistry, organic
EI chemistry, physical
EP computer science, artificial intelligence
ES computer science, hardware and architecture
EV computer science, interdisciplinary applications
EW computer science, software, graphics, programming
EY computer science, robotics
FF emergency medicine
FI crystallography
FQ cellular biology and histology
FY dentistry, oral surgery and medicine
GA dermatology and venereal disease
GC geochemistyr and geophysics
GM substance abuse
GU ecology
HB education, scientific disciplines
HQ electrochemistry
HY developmental biology
IA endocrinology and metabolism










JY food science and technology
KA forestry
KI gastroenterology and hepatology
KM genetics and heredity
KY geology
LI geriatrics and gerontology
MA hematology
MU horticulture
NE public, environmental and occupational health
NI immunology
NN infectious disease
OA instruments and instrumentation
OP medicine,legal32
PI marine and freswhater biology
PJ material science, paper and wood
PK material science, ceramics




PW medical laboratory technology
PY medicine, general and internal
PZ metallurgy and metallurgical engineering
QA medicine, research and experimental
QB medicine, miscellaneous
QE materials science, biomaterials
QG materials science, coatings and films
QJ materials science, textile
QM metallurgic and mine engineering








RY nuclear science and technology
SA nutrition and dietetics







TU pharmacology and pharmacy
UB physical, applied
UE imaging science and photographic technology
UH physics, atomic, molecular and chemical
UI physics, multidisciplinary









XE agriculture, soil science
XQ spectroscopy
XW sport sicences






ZA urology and nephrology
ZC veterinary sciences
ZD peripheral vascular disease
ZE virology
ZM zoology
ZR water resources